Bionano Genomics, Inc. Increase (Decrease) in Other Operating Assets
Bionano Genomics, Inc. (BNGO) reported Increase (Decrease) in Other Operating Assets of -$992.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2025-11-13
- Bionano Genomics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$326.00K.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-06-30 was -$336.00K.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-03-31 was -$330.00K.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for the quarter ending 2024-12-31 was -$1.00K.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$4.68M, a 193.19% decline from fiscal 2023.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for fiscal 2023 was $5.02M, a 344.25% increase from fiscal 2022.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for fiscal 2022 was $1.13M, a 74.65% increase from fiscal 2021.
- Bionano Genomics, Inc. increase (decrease) in other operating assets for fiscal 2021 was $647.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$662.00K derived: sum of 2 quarters · filed 2025-11-13 | -$992.00K 10-Q · filed 2025-11-13 | -$993.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | -$336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$666.00K 10-Q · filed 2025-08-14 | -$667.00K derived: sum of 3 quarters · filed 2025-08-14 | -$3.80M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | -$330.00K 10-Q · filed 2025-05-14 | -$331.00K derived: sum of 2 quarters · filed 2025-05-14 | -$3.46M derived: sum of 3 quarters · filed 2025-11-13 | -$4.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$3.13M derived: sum of 2 quarters · filed 2025-11-13 | -$3.89M derived: sum of 3 quarters · filed 2025-11-13 | -$4.68M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.89M derived: sum of 2 quarters · filed 2025-11-13 | -$4.68M 10-Q · filed 2025-11-13 | -$7.46M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$759.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.54M 10-Q · filed 2025-08-14 | -$4.32M derived: sum of 3 quarters · filed 2025-08-14 | $2.89M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$786.00K 10-Q · filed 2025-05-14 | -$3.56M derived: sum of 2 quarters · filed 2025-05-14 | $3.65M derived: sum of 3 quarters · filed 2025-05-14 | $3.86M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.43M derived: sum of 2 quarters · filed 2025-03-31 | $4.65M derived: sum of 3 quarters · filed 2025-03-31 | $5.02M 10-K · filed 2025-03-31 |
| 2023-09-30 | $7.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $7.43M derived: sum of 2 quarters · filed 2024-11-14 | $7.80M 10-Q · filed 2024-11-14 | $8.88M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $587.00K 10-Q · filed 2024-08-07 | $1.67M derived: sum of 3 quarters · filed 2024-08-07 | $1.63M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $372.00K 10-Q · filed 2024-05-08 | $1.45M derived: sum of 2 quarters · filed 2024-05-08 | $1.41M derived: sum of 3 quarters · filed 2024-05-08 | $1.45M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.04M derived: sum of 2 quarters · filed 2024-03-05 | $1.08M derived: sum of 3 quarters · filed 2024-03-05 | $1.13M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $4.00K derived: sum of 2 quarters · filed 2023-11-08 | $52.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $91.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $48.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $647.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |